Related Experiment Video
Updated: May 10, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Treatment strategies for peripheral T-cell lymphomas
1Yale University School of Medicine, New Haven, CT, USA. francine.foss@yale.edu
Best Practice & Research. Clinical Haematology
|June 18, 2013
Summary
Peripheral T-cell lymphomas (PTCL) are aggressive cancers with poor outcomes. New drug classes and molecular targets offer hope for patients resistant to conventional therapies.
Area of Science:
- Oncology
- Hematology
- Immunology
Background:
- Peripheral T-cell lymphomas (PTCL) represent aggressive hematologic malignancies.
- Conventional therapies yield suboptimal outcomes for many PTCL patients.
- Autologous stem cell transplantation improves survival but is not suitable for all.
Purpose of the Study:
- To review current therapeutic strategies for PTCL.
- To highlight emerging novel agents and molecular targets in PTCL treatment.
- To discuss the role of molecular profiling in guiding future therapies.
Main Methods:
- Literature review of clinical trials and preclinical studies.
- Analysis of data on novel drug classes and targeted therapies.
- Discussion of molecular pathways implicated in PTCL pathogenesis.
Main Results:
- Aggressive first-line therapy and stem cell transplantation improve survival in some PTCL patients.
- Many patients remain refractory to or relapse after current treatments.
- Emerging agents include antifolates, immunoconjugates, HDAC inhibitors, and signal transduction inhibitors.
Conclusions:
- PTCL remains a challenging disease with unmet therapeutic needs.
- Novel agents and targeted therapies show promise for improving PTCL outcomes.
- Molecular profiling is crucial for identifying new therapeutic strategies and personalized medicine approaches in PTCL.
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...